vCologuard® Expansion

3

The information and data presented here was prepared for investors and potential investors. It includes forward-looking information on investigational products in development that are not available for sale in the United States. These include early-stage development products for which the performance characteristics have not yet been established.

Multiple opportunities to expand Cologuard® use

• Evaluating broader US screening populations

– High-risk individuals (20M Americans)

– 40-49 year olds (40M Americans)

• Addressing these markets requires

– Clinical and pharmacoeconomic data

– Guideline committees support

– Regulatory support